F4 FundFund
TeamPortfolioRaiseChampionsEssays
Sign in
Investment ThesisInvestment TeamF4 Research BriefSelected PortfolioRecent UpdatesSimilar Firms
Warm Fund

Taiwania Capital

www.taiwaniacapital.com · Taipei City, Taiwan

“Taiwania Capital is a public-and-private-sector-backed venture platform that links capital, technology, and cross-border networks for technology and biotech companies.”

Leads
Lead Tendency
$865M
AUM
01Investment Thesis

Taiwania Capital is a public-and-private-sector-backed venture platform that links capital, technology, and cross-border networks for technology and biotech companies.

Exclusion Criteria

Not publicly specified; the public pattern suggests lower fit for generic consumer apps, non-technical teams, and businesses without a clear technology edge.

02Investment Team
DW
David Weng
CEO and General Partner of Tech / CEE / SEA Fund
IL
Ita Lu
Managing Partner of Tech / CEE Fund
RW
Richard Wang
Managing Partner of CEE / Tech Fund
TV
Tomas Vanco
Global Investment Manager
03F4 Research Brief

Taiwania Capital Research

Investment Thesis

Taiwania Capital presents itself as a cross-border venture platform built to connect capital, technology, and the Taiwan ecosystem. Its public materials describe the firm as a leading Taiwan VC supported by public and private sectors, founded in 2017, with a mission to partner with companies worldwide and help strengthen Taiwan's innovation economy. The site repeatedly emphasizes technology and biotech, and the portfolio pages show an especially broad appetite for AI, IoT, SaaS, robotics, semiconductors, cybersecurity, and life sciences.

The clearest pattern is that Taiwania looks for defensible technology businesses that can benefit from the firm's geographic network. The firm's own language is about linking technology and capital rather than simply writing checks. That shows up in how it frames companies like Orqa, Supernova, TransferGo, and the life science portfolio: the value is not only financing but also access to Taiwan, the US, Central and Eastern Europe, Southeast Asia, Japan, and industrial partners.

Stage Focus

Taiwania says it invests in companies at different stages, and the public portfolio suggests a bias toward early to growth stage opportunities. Its site and LinkedIn presence describe a focus on early-to-growth technology and biotech startups, while individual fund pages show stage-agnostic or broad regional deployment mandates in some vehicles.

The public record does not reduce cleanly to a single stage box. The firm has backed seed and Series A software and deep tech companies, but it also shows comfort with Series B and later life science or strategic rounds. A conservative read is that Taiwania is most active from Seed through Series B, with selective growth-stage participation when the company fits the firm's cross-border or strategic mandate.

Check Size

Taiwania does not publish a standard check-size policy on its public site. The most responsible answer is therefore that check size is not publicly disclosed.

The firm's public rounds range from strategic investments to larger lead positions, which suggests flexibility rather than a fixed, narrowly advertised check band. Public news is consistent with a firm that can lead or participate across several fund sleeves, but there is not enough source-backed detail to state a numeric range confidently.

Lead Tendency

Taiwania appears capable of both leading and participating, but its recent news shows multiple lead positions. It led Supernova's Series A, led APrevent Medical's Series D, and the TaiAx life science vehicle led Rakuten Medical's Series F. It also joined Orqa's Series A and made a strategic investment in TransferGo.

That pattern supports a leads label with some caution: the firm is not purely a passive follower, but it also uses participation where the strategic fit is strong and another investor or fund structure is taking the lead.

Recent Activity

The most recent public activity on the firm's site is the March 18, 2026 Orqa investment, where Taiwania's CEE Fund joined a €12.7 million Series A to support a resilient non-Chinese UAV supply chain. Earlier, the January 7, 2026 Rakuten Medical Series F announcement showed the TaiAx life science joint venture leading a $100 million round.

Other recent public investments include Supernova in September 2025, Tantti's acquisition announcement in July 2024, TransferGo in April 2024, and APrevent Medical in April 2024. Taiwania also announced the launch of the TaiAx Life Science Fund in August 2024, which is useful context because it explains how the firm is expanding its life science coverage through a dedicated joint venture structure.

Portfolio Highlights

The portfolio page shows a broad but coherent mix of technical companies:

  • Orqa, a Croatian FPV and UAS company focused on a non-Chinese drone supply chain
  • Supernova, an AI-powered design-to-code and design-system platform
  • TransferGo, a cross-border money movement platform
  • APrevent Medical, a voice and speech disorder medtech company
  • Rakuten Medical, a precision oncology and photoimmunotherapy company
  • Path Robotics, an AI welding automation company
  • TXOne Networks, an OT security platform
  • DataPelago, an AI and analytics data processing company
  • Landing AI, an intelligent document and vision AI company
  • Resemble AI, a generative AI security platform

The mix reinforces Taiwania's preference for technically complex products with global scalability and real operational utility.

Team

The site surfaces a distributed team across tech, CEE, SEA, and bio coverage.

  • David Weng, CEO and General Partner of Tech / CEE / SEA Fund
  • Ita Lu, Managing Partner of Tech / CEE Fund
  • Richard Wang, Managing Partner of CEE / Tech Fund
  • Tomas Vanco, Global Investment Manager
  • Hsin-Fu Huang, CFA, Managing Partner of SEA Fund

The team composition matches the firm's thesis: it is not a single-theme, single-market fund, but a networked platform that can source and support companies across regions and sectors.

Decision Process

Public materials do not describe a formal IC workflow or timeline. The best source-backed characterization is that Taiwania operates as a partnership-oriented investor that emphasizes access to networks, strategic collaboration, and regional expansion support.

The firm repeatedly describes its role as helping companies bridge markets and ecosystems. That implies a collaborative decision process rather than a purely transactional one, but the exact cadence and approval chain are not publicly documented.

Founder Preferences

Taiwania seems to prefer technical founders, especially teams building hard products or technically differentiated software with cross-border relevance. The portfolio suggests comfort with founders who can work across supply chains, regulated markets, or enterprise workflows, and with teams that can use Taiwania's network to open channels in Taiwan, the US, Japan, Southeast Asia, or Central and Eastern Europe.

A practical founder fit for Taiwania is a team that can explain why the company needs a global platform advantage, not just capital. The public messaging is strongest when the company has a real technology edge, operational depth, and a path to industrial or enterprise adoption.

Geographic Focus

Geographically, Taiwania is anchored in Taipei but operates with an international footprint. The public site lists Taipei City as the main office and Santa Clara as a US office, while the funds and portfolio show active coverage of Taiwan, the US, Japan, Southeast Asia, and Central and Eastern Europe.

That geographic spread is part of the firm's identity. Taiwania is not simply a domestic Taiwanese fund; it is built to connect Taiwan with strategic technology ecosystems elsewhere, especially where there is a clear industrial, supply-chain, or commercialization bridge.

04Selected Portfolio
Biotech & Life Sciences
Rakuten Medical·APrevent Medical
Enterprise Software
Supernova·Path Robotics·DataPelago·LandingAI·Resemble AI·Opsera·Verana Networks
Fintech & Payments
TransferGo
Gaming
Orqa
Security & Cybersecurity
TXOne Networks
Semiconductors & Hardware
Skymizer
Open the full portfolio→
05Recent Updates

Fresh signals from public announcements, essays, and portfolio activity.

See full activity (7) →
Taiwania's CEE Fund joined Orqa's €12.7 million Series A to support a resilient non-Chinese UAV supply chain.
INVESTMENT·taiwaniacapital.com
MAR 18, 2026
The TaiAx life science joint venture led Rakuten Medical's $100 million Series F.
INVESTMENT·taiwaniacapital.com
JAN 7, 2026
Taiwania led Supernova's $9.2 million Series A to scale its design-to-code platform.
INVESTMENT·taiwaniacapital.com
SEP 30, 2025
Taiwania and Axil Capital launched TaiAx Life Science Fund L.P. to back life science innovation.
NEW FUND·taiwaniacapital.com
AUG 27, 2024
Repligen announced an agreement to acquire Tantti Laboratory, marking a portfolio exit.
EXIT·taiwaniacapital.com
JUL 31, 2024
06Similar Firms
IC
Ince Capital
Seed · Series A
→
IC
IDG Capital
$1M – $100M · Seed · Series A
→
KI
Korea Investment Management Co.
$500K – $100M · Seed · Series A
→
T
TSVC
$250K – $3M · Pre-Seed · Seed
→
LC
Lux Capital
$100K – $100M · Pre-Seed · Seed
→
Quick Reference
Stages
Seed · Series A · Series B · Growth
AUM
$865M
Decision
Partnership
Location
Taipei City, Taiwan
Sector Focus
Biotech & Life SciencesSemiconductors & HardwareRobotics & AutomationEnterprise SoftwareDeveloper Tools & InfrastructureSecurity & CybersecurityHealthcare & Digital Health
Models
B2B SaaSDeveloper ToolsBiotechMedtechIndustrial TechAI Infrastructure
Technology
Ai MlComputer VisionHardwareIotBiotech Tech
See all Biotech & Life Sciences investors →See all Semiconductors & Hardware investors →See all Robotics & Automation investors →
Visit www.taiwaniacapital.com ↗

See how Taiwania Capital matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Focus Areas
Biotech & Life SciencesSemiconductors & HardwareRobotics & AutomationEnterprise SoftwareDeveloper Tools & InfrastructureSecurity & CybersecurityHealthcare & Digital Health

See how Taiwania Capital matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Is this your firm? Claim your profile
F4 Intelligence Report · Last Researched July 13, 2026F4 Research Engine